Results 1 to 10 of about 2,436,179 (328)
Valuing rural hospitals - the Australian experience
Rural and Remote Health, 2023 Introduction: Over many years in Australia, public hospitals were funded on historical grounds with about 40% of running costs provided by the national government.
Alan Chater, Samuel Webster
doaj +1 more source
Health Services Insights, 2023 In a bid to improve quality of care, numerous countries have incorporated rewards and penalties into the funding and pricing of hospital services. This paper outlines recent advances in Australia to incorporate financial penalties for hospital acquired ...
Samuel B. G. Webster +4 more
doaj +1 more source
EJC Supplements, 2021 Aim: To evaluate the cost-effectiveness of [177Lu]Lu-DOTA-TATE versus relevant comparators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-NETs) and the pancreas (P-NETs).
Matthew Glover +3 more
doaj +1 more source
Diagnostics, 2023 Antimicrobial resistance is a major global health threat, which is increased by the irrational use of antibiotics, for example, in the treatment of respiratory tract infections in community care.
Caroline Steigenberger +2 more
doaj +1 more source
Public spending on orphan medicines: a review of the literature
Journal of Pharmaceutical Policy and Practice, 2020 Background and objective Little is known about how much public payers spend on orphan medicines. This study aimed at identifying information on orphan medicine expenditure incurred by public payers that was published in literature globally and at ...
Margit Gombocz, Sabine Vogler
doaj +1 more source
Antibiotics, 2022 Point-of-care diagnostic tests for community-acquired acute respiratory tract infections (CA-ARTI) can support doctors by improving antibiotic prescribing.
Sabine Vogler, Friederike Windisch
doaj +1 more source
Comparison of Cardiovascular Medicines Prices in Four European Countries
Frontiers in Public Health, 2020 The aim of the current study was to compare pricing methodologies at the manufacturer, wholesale, and retail levels, and to estimate the price differences of AT1-receptor blockers (sartans), Angiotensin-converting enzyme (ACE)—inhibitors, and their fixed-
Zornitsa Mitkova +8 more
doaj +1 more source
Bounding the efficiency of road pricing [PDF]
, 2009 This paper deals with the following question associated with congestion pricing in a general network with either fixed or elastic travel demand: what is the maximum efficiency loss of a general second-best pricing scheme due to inexact marginal-cost ...
Heydecker, B.G., Xu, W., Yang, H.
core +2 more sources
Health and Quality of Life Outcomes, 2020 Background A Task Force from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) provides recommendations on how to systematically identify and appraise health state utility (HSU) weights for cost-effectiveness analyses.
Jacie T. Cooper +5 more
doaj +1 more source
The Pricing of Options and Corporate Liabilities
Journal of Political Economy, 1973 If options are correctly priced in the market, it should not be possible to make sure profits by creating portfolios of long and short positions in options and their underlying stocks.
F. Black, Myron S. Scholes
semanticscholar +1 more source